Chemotherapy of Advanced Renal Cell Carcinoma: Results of Treatment with Methyl-Glyoxal Bis-Guanylhydrazone (methyl-GAG): An Eortc Study

  • J. A. Child
  • G. Stoter
  • S. D. Fosså
  • A. V. Bono
  • M. de Pauw
  • EORTC Urological Group
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


The range of drugs which have been thoroughly tested in advanced renal cancer is still limited. Few oncologists have been able to accumulate sufficient experience of the treatment of adequate numbers of patients. Results of single agent therapy have recently been reviewed by Bodey (1) and de Kernion (2). It is uncertain whether any agent yet tested can be regarded as effective but there is some evidence to suggest that vinblastine may be, Hrushesky and Murphy (3) reporting a 25% objective response rate — including three complete remissions of up to four years duration — in a series of 135 patients. Other reports on the activity of vinblastine have been less encouraging (2). In recent studies, methodichlorophen has been shown to be inactive (4) as has 4-epi-adriamycin (5). A variety of chemothera-peutic combinations have been investigated with disappointing results. A combination of adriamycin, vincristine and medroxyprogesterone acetate with BCG was reported as giving a 33% overall response (6) and vinblastine plus CCNU a 24% response (7). There is no evidence that any combination studied is superior to vinblastine when used as a single agent. It is clear that there is a continuing urgent need to evaluate untested, especially new, chemotherapeutic agents in renal cell carcinoma.


Renal Cell Carcinoma Partial Remission Renal Carcinoma Medroxyprogesterone Acetate Advanced Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G.P. Bodey, Current Status of Chemotherapy in Metastatic Renal Carcinoma, in “Cancer of the Genitourinary Tract,” D.E. Johnson and M.L. Samuels (eds), Raven Press, New York. (1979) p.67.Google Scholar
  2. 2.
    J.B. de Kernion, Renal Cell Carcinoma, in “Cancer Treatment,” C.H. Haskell (ed), Saunders, Philadelphia. (1980) p.392.Google Scholar
  3. 3.
    W.J. Hrushesky and G.P. Murphy, Current Status of the Therapy of Advanced Renal Carcinoma, J. Surg. Oncol. 9:277 (1977).PubMedCrossRefGoogle Scholar
  4. 4.
    J.R. Hindmarsh, R.R. Hall and A.E. Kulatilake, Renal Cell Carcinoma: A Preliminary Clinical Trial of Methodichlorophen, Clin. Oncol. 5:11 (1979).PubMedGoogle Scholar
  5. 5.
    S.D. Fossa, B. Wik, E. Bae and H.H. Lien, 4′-Epi-Adriamycin in Metastatic Renal Cancer, in “Cancer of the Prostate and Kidney,” P.H. Smith and M. Pavone-Macaluso (eds), Plenum, London and New York. (1982).Google Scholar
  6. 6.
    D.R. Ishmael, L.J. Burop and R.H. Bottomley, Combined Therapy of Advanced Hypernephroma with Medroxyprogesterone, BCG, Adriamycin and Vincristine (Abstract C-403), Proc. Am. Assoc. Cancer Res. Am. Soc. Clin. Oncol. 19:407 (1978)Google Scholar
  7. 7.
    T.E. Davis and F.B. Manado, Combination Chemotherapy of Advanced Renal Cancer with CCNU and Vinblastine (Abstract C-39), Proc. Am. Assoc. Cancer Res. Am. Soc. Clin. Oncol. 19:316 (1978).Google Scholar
  8. 8.
    R.H. Levin, E. Henderson, M. Karon and E.J. Freireich, Treatment of Acute Leukaemia with Methylglyoxal Bis Guanylhydrazone (methyl-GAG), Clin. Pharmacol. Ther. 6:31 (1964).Google Scholar
  9. 9.
    P.P. Carbone, E.J. Freireich, E. Frei III, D.P. Rall, M. Karon and C.O. Brindley, The Effectiveness of Methylglyoxal Bis Guanylhydrazone in Human Malignant Disease, Acta Unio Internat. Contra Cancrum, 20:340 (1964).Google Scholar
  10. 10.
    W.A. Knight III, R.B. Livingston, C. Fabian and J. Costanzi, Methylglyoxal Bis-Guanylhydrazone (methyl-GAG, MGBG) in Advanced Human Malignancy, Proc. Am. Assoc. Cancer Res. 20:319 (1979).Google Scholar
  11. 11.
    W.A. Knight III, R.B. Livingston, C. Fabian and J. Costanzi, Phase I-II Trial of Methyl-GAG: A Southwest Oncology Group Pilot Study, Cancer Treat. Rep. 63:1933 (1979).PubMedGoogle Scholar
  12. 12.
    W.A. Knight III, R.B. Livingston, C. Fabian and J. Costanzi, Methyl-Glyoxal Bis-Guanylhydrazone (methyl-GAG, MGBG) in Advanced Renal Carcinoma, Proc. Am. Assoc. Cancer Res. 21:367 (1980).Google Scholar
  13. 13.
    J. Killin, D. Hoth, F. Smith, P. Schein and P. Woolley, Methyl-Glyoxal Bis-Guanylhydrazone (NSC 32946)(methyl-GAG) Phase II Experience and Clinical Pharmacology, Proc. Am. Assoc. Cancer Res. 21:368 (1980).Google Scholar
  14. 14.
    R.F. Todd, M.D. Garnick and G.P. Canellos, Chemotherapy of Advanced Renal Adenocarcinoma with Methyl-Glyoxal Bis-Guanylhydrazone (methyl-GAG), Proc. Am. Assoc. Cancer Res. 21:340 (1980).Google Scholar
  15. 15.
    C.W. Porter, D. Mikles-Robertson, D. Kramer and C. Dave, Correlation of Ultrastructural and Functional Damage to Mitochondria of Ascites L1210 Cells Treated In Vivo with Methylglyoxal Bis (Guanylhydrazone) or Ethidium Bromide, Cancer Res. 39:2414 (1979).PubMedGoogle Scholar
  16. 16.
    V.T. Oliverio, R.H. Adamson, E.S. Henderson and J.D. Davidson, The Distribution, Excretion and Metabolism of Methylglyoxal Bis (Guanylhydrazone C14), J. Pharmacol. & Exper. Therap. 141:149, (1963).Google Scholar
  17. 17.
    WHO Handbook for Reporting Results of Cancer Treatment, Definitions of Objective Response, WHO Offset Publication, 48:23 (1979).Google Scholar
  18. 18.
    J. Zeffren, A. Yagoda, R.C. Watson, R.B. Natale, M.S. Blumenreich and J. Howard, Phase II Trial of Methyl-Glyoxal Bis-Guanylhydrazone in Advanced Renal Cancer, Cancer. Treat. Rep. 65:525 (1981).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. A. Child
    • 1
  • G. Stoter
  • S. D. Fosså
  • A. V. Bono
  • M. de Pauw
  • EORTC Urological Group
  1. 1.The General Infirmary at LeedsEngland UK

Personalised recommendations